Pearson/health claims forum
This article was originally published in The Tan Sheet
Executive Summary
FDA will hold a public meeting April 4 to solicit input on two dietary supplement labeling issues: implementation of the Pearson v. Shalala decision and whether claims about an effect on an existing disease should constitute a health claim or subject the product to drug regulation. In a March 3 letter to the dietary supplement community, FDA says a Federal Register notice detailing specific issues, logistics and registration information will be published shortly. Implementation of the Pearson vs. Shalala decision and development of a policy on disease-related statements are among CFSAN's "A-list" priorities for 2000 (1"The Tan Sheet" Feb. 14, p. 12)